Marcus Michael Fischer

Title: Innovations of Marcus Michael Fischer

Introduction

Marcus Michael Fischer is an accomplished inventor based in South San Francisco, CA. He holds 2 patents that contribute significantly to the field of cancer treatment and molecular biology. His work focuses on developing innovative compounds that target specific biological processes.

Latest Patents

Fischer's latest patents include "Thiadiazolyl derivatives as DNA polymerase theta inhibitors and uses thereof." This patent discloses compounds that inhibit DNA Polymerase Theta (Polθ) activity, particularly by inhibiting the ATP-dependent helicase domain activity of Polθ. The patent also covers pharmaceutical compositions that utilize these compounds for treating diseases, including homologous recombination (HR) deficient cancers. Another notable patent is for a "Combination therapy comprising a MAT2A inhibitor and a type II PRMT inhibitor." This combination product is designed to treat various cancers, including solid tumors, by targeting MAT2A-associated and/or PRMT-associated diseases.

Career Highlights

Throughout his career, Fischer has worked with prominent companies such as Ideaya Biosciences, Inc. and GlaxoSmithKline Intellectual Property Limited. His contributions to these organizations have been instrumental in advancing cancer research and treatment methodologies.

Collaborations

Fischer has collaborated with notable colleagues, including Claire L. Neilan and Michael Patrick Dillon. These partnerships have fostered a collaborative environment that enhances innovation and research in the field.

Conclusion

Marcus Michael Fischer's innovative work and patents reflect his commitment to advancing cancer treatment through targeted molecular therapies. His contributions continue to impact the scientific community and improve patient outcomes.